Leading Pharmaceutical Manufacturer Simplifies Contract and Rebate Processes
Raritan, NJ – September 16, 2014 – iContracts, a leading provider of solutions for managing corporate contracts, commitments, and compliance today announced that Meda Pharmaceuticals, has gone live with iContracts Rebate Payer, Utilization Payer and Universal Contract Manager (UCM), to strengthen compliance and effectively manage revenue.
Meda Pharmaceuticals utilizes iContracts solutions as a software service over the web, thus requiring no investment in facilities, hardware, software, or related costs. iContracts Rebate Payer manages rebates and incentive-based contracts, including calculations based on direct and indirect sales, net sales, utilization payments and more. Utilization Payer allows Meda to manage, validate and pay managed care rebate agreements. Universal Contract Manager enables Meda to harness contracts of all types across the enterprise, enabling the management of every contract lifecycle, including contract creation, monitoring of key milestones, and compliance.
“We are gratified to be working together with such a well-known and respected pharmaceutical manufacturer such as Meda on this important initiative,” commented Leigh Powell, Chief Executive Officer of iContracts. “While the promise of rapid implementation and time-to-value is widely claimed by many solution providers, iContracts’ ability to consistently deliver on this promise sets us apart and continues to drive our success in the life sciences market.”
iContracts’ solutions are available as an “on demand” service or as a behind-the-firewall offering and are built on iContracts’ revolutionary BCS platform featuring an advanced data architecture, rich functionality and Simplified Common User Interface (SCUI) enabling users to execute any process after learning just two basic page formats. This groundbreaking design drastically reduces implementation; training and future upgrade timeframes and costs. iContracts offers a competitive migration program for organizations who are thinking about making a change from their existing platform.
About iContracts
iContracts’ goal is simple – to deliver better solutions for managing contracts that are faster, easier and less expensive to implement. This mantra is reflected in everything we do. Our software is generations ahead of other solutions, powered by a Simplified Common User Interface (SCUI) that makes every user an “expert” by learning just two simple, reusable views and backed by the most highly evolved data architecture in the industry – built by technologists with considerable and unique experience in building contract management solutions. This deep understanding and straightforward approach shows in everything we do. iContracts comprehensive suite of solutions manages all aspects of a company’s contract management process. iContracts Universal Contract Manager (UCM) is revolutionizing how organizations think about the contract management process, transforming it from an unwieldy collection of spreadsheets, customer applications, filing cabinets, and scattered electronic directories to a powerful tool that aligns strategy with execution, while simultaneously insuring greater visibility into commitments and the ability of companies to support growing needs for regulatory reporting and audits. Our solutions are enterprise-class and can be quickly and easily integrated with any off-the-shelf or custom system to meet exacting business requirements without the army of consultants and endless fees associated with other products and providers. For more information, please contact us.
About Meda Pharmaceuticals
MEDA PHARMACEUTICALS INC. is the U.S. subsidiary of Meda AB. Meda is a leading international specialty pharma company with a broad product portfolio and its own sales organizations in almost 60 countries. Including those markets where sales are managed by distributors, Meda’s products are sold in more than 120 different countries. Meda AB is the Group’s parent company and its headquarters are located in Solna outside of Stockholm.